Pancreatic alpha-amylase (AMY2) (AMY2)

Pancreatic alpha-amylase is a calcium-dependent hydrolase secreted by the pancreas that plays a critical role in the initial stages of carbohydrate digestion by catalyzing the hydrolysis of alpha-1,4-glycosidic linkages in starch and glycogen (StatPearls, 2023). This enzymatic activity produces maltose, maltotriose, and alpha-limit dextrins, which are subsequently converted to glucose by brush-border enzymes for systemic absorption (UniProt P04746). In the management of metabolic disorders, this enzyme serves as a primary therapeutic target for controlling postprandial hyperglycemia in patients with type 2 diabetes mellitus and obesity (PubMed, PMID: 22039799). Pharmacological inhibitors, such as acarbose, bind competitively to the enzyme's active site, thereby delaying the breakdown of complex carbohydrates and slowing the rate of glucose entry into the circulation (PubChem, CID 41774). While effective for glycemic control, the inhibition of this enzyme often leads to gastrointestinal side effects, including flatulence and diarrhea, due to the fermentation of undigested carbohydrates by colonic bacteria (NIH, 2022). Additionally, clinical measurement of serum pancreatic amylase levels is a standard diagnostic biomarker for assessing pancreatic function and detecting acute pancreatitis (Mayo Clinic, 2023).

Other names

1,4-alpha-D-glucan glucanohydrolasePancreatic amylaseAMY2AAMY2BAlpha-amylase 2Mammalian pancreatic alpha-amylase

Competitive inhibition of alpha-1,4-glycosidic bond hydrolysis in polysaccharides (PubChem, CID 41774)